Skip to main content

Volume 16, Issue 2 (Spring 2015)  [12]

Persistent link to this collection:

Recently Added

Autonomous and Automated and Connected Cars—Oh My! First Generation Autonomous Cars in the Legal Ecosystem

Glancy, Dorothy, J. (Minnesota Journal of Law, Science & Technology, 2015)
This Article considers the legal system that awaits the first fully autonomous passenger vehicles to reach consumer markets. These first generation autonomous cars will be an initial step beyond conventional, human-directed ...

Should You Know About the Pesticides in Your Clothes? Nanosilver and the Treated Articles Exemption to FIFRA

Meinert, James (Minnesota Journal of Law, Science & Technology, 2015)
This Note explores EPA’s statutory authority to regulate pesticides, and the policies EPA has adopted to regulate pesticides used to preserve consumer products. The use of nanosilver—small particles of silver under 100 ...

Is Groundwater that Is Hydrologically Connected to Navigable Waters Covered Under the CWA?: Three Theories of Coverage & Alternative Remedies for Groundwater Pollution

Kvien, Allison L. (Minnesota Journal of Law, Science & Technology, 2015)
The EPA’s interpretation that directly connected groundwater is within the scope of the CWA’s jurisdiction has been accepted with varying degrees of success among the federal district and circuit courts. Some courts have ...

The Hydropower Regulatory Efficiency Act: Not Giving a Dam for Negative Externalities or Stakeholder Oversight

Cumming, Catherine (Minnesota Journal of Law, Science & Technology, 2015)
In an effort to streamline FERC’s regulatory process and promote the development of small-scale hydropower projects, Congress passed the Hydropower Regulatory Efficiency Act of 2013 (the Act), also known as the 1040-EZ of ...

Biosimilar Regulation: Bringing the United States Up To Speed with Other Markets

Banthia, Vinita (Minnesota Journal of Law, Science & Technology, 2015)
In light of the expected end of patent terms for many large molecule drugs called biologics, there has been a rise in the development of biosimilars—non-branded, copycat versions of biologics. Unlike generic drugs, which ...

View more